Merck KGaA’s Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus
Merck KGaA (ETR: MRK) announced on July 8, 2026, that the US Food and Drug...
Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset
Braveheart Bio, a Delaware-based biopharmaceutical company founded in 2024, submitted its IPO prospectus to the...
WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028
WuXi Biologics (HKG: 2269) announced on June 16, 2026, a comprehensive Contract Development, Research, and...
China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) issued the...
Johnson & Johnson Reports Q2 2026 Results with 6.6% Sales Growth, Raises Full-Year Guidance
Johnson & Johnson (J&J) (J&J, NYSE: JNJ) announced second-quarter 2026 results, reporting sales growth of...
Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics
Innovent Biologics (HKG: 1801) announced an exclusive license agreement with Spero Therapeutics, Inc. (NASDAQ: SPRO)...
Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger
Hansoh Pharmaceutical (HKG: 3692) announced a dual strategic transaction involving its portfolio company Avere Therapeutics,...
Everest Medicines and JD Healthcare Forge Strategic Digital Healthcare Alliance to Accelerate Innovative Drug Access
Everest Medicines (HKG: 1952) announced a strategic cooperation agreement with JD Healthcare (HKG: 6618) to...
Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H/dMMR Colon Cancer
Innovent Biologics (HKG: 1801) announced that its independently developed Daboxin (ipilimumab N01) has received marketing...
Kelun-Biotech’s Sacituzumab Tirumotecan Achieves World’s First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that its Phase III clinical study evaluating sacituzumab...
CSPC Pharmaceutical Secures Dual NMPA Breakthrough Therapy Designations for HER2-Positive Breast Cancer Combination
CSPC Pharmaceutical Group (HKG: 1093) announced that its self-developed docetaxel (albumin-bound) (HB1801) and Anbenitamab (KN026)—developed...
Biogen Advances Diranersen into Phase 3 Development Following Positive Alzheimer’s Phase 2 Data
Biogen Inc. (NASDAQ: BIIB) presented positive Phase 2 CELIA study data for diranersen (BIIB080), an...
Sino Biopharmaceutical’s TRD205 Secures NMPA Breakthrough Therapy Designation for Chronic Post-Surgical Neuropathic Pain
Sino Biopharmaceutical (HKG: 1177) announced that TRD205, a Category 1 innovative drug self-developed by its...
Insilico Medicine and Bora Pharmaceuticals Forge $2.5B Strategic Alliance to Pioneer AI-Driven Drug R&D
Insilico Medicine (HKG: 3696) announced a strategic alliance with Bora Pharmaceuticals (TPE: 6472; OTCMKTS: BORAY)...
Lynk Pharmaceuticals Completes Phase 3 Enrollment for Zemprocitinib in Ankylosing Spondylitis Trial
Lynk Pharmaceuticals Co., Ltd. announced that enrollment has been completed for zemprocitinib capsules, a second-generation...
CR Pharmaceutical Commercial and Innovent Biologics Forge Strategic Partnership to Build Integrated Health Management Ecosystem
CR Pharmaceutical Commercial Group and Innovent Biologics (HKG: 1801) have signed a strategic cooperation agreement...
China’s State Council Unveils “15th Five-Year” National Health Plan with Strong Support for Innovative Therapeutics and AI Integration
China’s State Council has issued the “15th Five-Year” National Health Plan, outlining an ambitious roadmap...
Haisco Pharmaceutical Secures NMPA IND Acceptance for HSK60002 Tablets in Inflammatory Diseases
Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the Investigational New Drug (IND) application...
China’s NHSA Completes Preliminary Review of 2026 Medical Insurance Catalog with 91% Pass Rate for Basic Medicines
China’s National Healthcare Security Administration (NHSA) announced the completion of its preliminary formal review for...
B&K Corporation Completes Patient Enrollment in Phase II Diabetic Foot Ulcer Trial for Pro-101-2 rhPDGF-BB Therapy
B&K Corporation Limited (HKG: 2396) announced the completion of patient enrollment in its Phase II...